Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

By J. Seymour, T. Kipps, B. Eichhorst, P. Hillmen, J. D’Rozario, S. Assouline, C. Owen, J. Gerecitano, T. Robak, J. de la Serna and 10 more. New England Journal of Medicine, 2018

792 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/6473a7c9b5aa6ed622898f260764ee04801959f7

Citations in the corpus

• Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL (2018, neutral): “(%)§ 143/499 (29) 44/166 (27) 39/165 (24) 60/168 (36) 0.”